The ATM inhibitor (ATMi; KU-60019) and ATR inhibitor (ATRi; AZD6738) potently inhibit their target and effectively sensitised glioma cells (ATMi) and NSCLC cells (ATRi) to radiation and were used at doses with confirmed target inhibition18,19. This evidence concerns the gene ATR and central nervous system cancer.